Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H27N3O3S.ClH |
Molecular Weight | 449.994 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN(CC)CC)C=C1
InChI
InChIKey=VHNXQKLWIQHSOY-UHFFFAOYSA-N
InChI=1S/C22H27N3O3S.ClH/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3;/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27);1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15798717
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15798717
Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other Commonwealth of Independent States countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0086001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2538064 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ethacyzin Approved UseUnknown |
|||
Primary | Ethacyzin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_5522.htm
The initial dose is 50 mg (1 table) 2-3 times a day. In case of insufficient clinical effect, the dose is increased (under compulsory ECG monitoring) to 50 mg 4 times a day (200 mg) or 100 mg 3 times daily (300 mg).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6882907
Ethacizine applied in the concentration range between 1 X 10(-7) and 1 X 10(-5) g/ml decreased the rate of action potential growth (Vmax) of the mammal myocardium. Inhibition of the Vmax was accompanied by the diminution of the force of contraction which involved two phases. Ethacizine also decreased the overshoot of slow response action potential with the time constant similar to that in the first rapid phase of force reduction.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
260059T81O
Created by
admin on Sat Dec 16 01:43:16 GMT 2023 , Edited by admin on Sat Dec 16 01:43:16 GMT 2023
|
PRIMARY | |||
|
3044577
Created by
admin on Sat Dec 16 01:43:16 GMT 2023 , Edited by admin on Sat Dec 16 01:43:16 GMT 2023
|
PRIMARY | |||
|
57530-40-2
Created by
admin on Sat Dec 16 01:43:16 GMT 2023 , Edited by admin on Sat Dec 16 01:43:16 GMT 2023
|
PRIMARY | |||
|
300000046980
Created by
admin on Sat Dec 16 01:43:16 GMT 2023 , Edited by admin on Sat Dec 16 01:43:16 GMT 2023
|
PRIMARY | |||
|
DTXSID80206149
Created by
admin on Sat Dec 16 01:43:16 GMT 2023 , Edited by admin on Sat Dec 16 01:43:16 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD